Susquehanna International Group
CLVS

Susquehanna International Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Susquehanna International Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-484,400
Closed -$576K – 14377
2022
Q3 		$576K Sell
484,400
-84,400
-15% -$132K ﹤0.01% 8112
2022
Q2 		$1.02M Buy
568,800
+107,500
+23% +$159K ﹤0.01% 6485
2022
Q1 		$932K Sell
461,300
-8,400
-2% -$16.5K ﹤0.01% 7308
2021
Q4 		$1.27M Sell
469,700
-317,300
-40% -$1.17M ﹤0.01% 6632
2021
Q3 		$3.51M Sell
787,000
-47,300
-6% -$228K ﹤0.01% 4619
2021
Q2 		$4.84M Sell
834,300
-34,100
-4% -$200K ﹤0.01% 4094
2021
Q1 		$6.1M Buy
868,400
+159,500
+22% +$1.07M ﹤0.01% 3537
2020
Q4 		$3.4M Buy
708,900
+238,300
+51% +$1.21M ﹤0.01% 4090
2020
Q3 		$2.74M Sell
470,600
-23,900
-5% -$143K ﹤0.01% 4028
2020
Q2 		$3.34M Sell
494,500
-659,600
-57% -$4.99M ﹤0.01% 3623
2020
Q1 		$7.34M Sell
1,154,100
-906,700
-44% -$7.27M ﹤0.01% 2103
2019
Q4 		$21.5M Buy
2,060,800
+1,614,400
+362% +$11.7M 0.01% 1352
2019
Q3 		$1.75M Buy
446,400
+187,300
+72% +$1.52M ﹤0.01% 4487
2019
Q2 		$3.85M Sell
259,100
-33,300
-11% -$602K ﹤0.01% 3081
2019
Q1 		$7.26M Sell
292,400
-537,300
-65% -$13.5M ﹤0.01% 2054
2018
Q4 		$14.9M Buy
829,700
+536,400
+183% +$11M 0.01% 1277
2018
Q3 		$8.61M Sell
293,300
-915,900
-76% -$35.5M ﹤0.01% 2090
2018
Q2 		$55M Buy
1,209,200
+911,700
+306% +$44.3M 0.02% 646
2018
Q1 		$15.7M Sell
297,500
-548,100
-65% -$32M 0.01% 1405
2017
Q4 		$57.5M Buy
845,600
+420,500
+99% +$29.4M 0.02% 628
2017
Q3 		$35M Sell
425,100
-241,200
-36% -$19.1M 0.01% 845
2017
Q2 		$62.4M Buy
666,300
+364,000
+120% +$22.3M 0.03% 515
2017
Q1 		$19.2M Sell
302,300
-36,000
-11% -$2.19M 0.01% 1099
2016
Q4 		$15M Sell
338,300
-200,500
-37% -$7.06M 0.01% 1250
2016
Q3 		$19.4M Buy
538,800
+222,200
+70% +$4.77M 0.01% 1035
2016
Q2 		$4.34M Sell
316,600
-242,800
-43% -$3.55M ﹤0.01% 2392
2016
Q1 		$10.7M Buy
559,400
+281,900
+102% +$5.97M 0.01% 1484
2015
Q4 		$9.71M Buy
277,500
+2,400
+0.9% +$155K ﹤0.01% 1784
2015
Q3 		$25.3M Sell
275,100
-44,300
-14% -$3.83M 0.01% 1025
2015
Q2 		$28.1M Buy
319,400
+179,400
+128% +$15.4M 0.01% 1032
2015
Q1 		$10.4M Sell
140,000
-162,900
-54% -$11.5M ﹤0.01% 1837
2014
Q4 		$17M Buy
302,900
+76,600
+34% +$4.03M 0.01% 1484
2014
Q3 		$10.3M Buy
226,300
+38,000
+20% +$1.59M ﹤0.01% 2084
2014
Q2 		$7.8M Buy
188,300
+24,100
+15% +$1.24M ﹤0.01% 2422
2014
Q1 		$11.4M Buy
164,200
+118,000
+255% +$8.67M 0.01% 1869
2013
Q4 		$2.78M Sell
46,200
-156,300
-77% -$8.5M ﹤0.01% 3755
2013
Q3 		$12.3M Buy
+202,500
New +$14.4M 0.01% 1674

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Susquehanna International Group's CLVS Position: Q4 2022 in Review

Susquehanna International Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 505,343 shares — an estimated $601K sold.

Susquehanna International Group first reported a position in CLVS in Q2 2013 and held it in 37 quarters. The position peaked at $24.9M in Q4 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Susquehanna International Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Susquehanna International Group sold 505,343 Clovis Oncology, Inc. shares in Q4 2022, an estimated $601K.
  • Susquehanna International Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 37 quarters.
  • Susquehanna International Group's Clovis Oncology, Inc. position peaked at $24.9M in Q4 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.